Monitoring platelet activation in patients with aneurysmal subarachnoid hemorrhage
Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage
This study is testing how changes in platelets in the blood affect brain health in patients who have had bleeding in the brain due to an aneurysm.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 2 sites (Bron, Auvergne-Rhône-Alpes and 1 other locations) |
| Trial ID | NCT06375889 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the role of platelet activation in patients suffering from delayed cerebral ischemia following an aneurysmal subarachnoid hemorrhage. It focuses on understanding the relationship between platelet kinetics and vascular dysfunction over time, which may contribute to secondary neuronal loss. Blood tests will be conducted to monitor platelet activation in hospitalized patients at the Pierre Wertheimer Hospital. The study seeks to clarify the pathophysiology of delayed cerebral ischemia and its complications.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been hospitalized for aneurysmal subarachnoid hemorrhage and are admitted to the neurological intensive care unit.
Not a fit: Patients with non-aneurysmal subarachnoid hemorrhage, ischemic stroke, or known platelet function disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of delayed cerebral ischemia, potentially reducing morbidity and mortality in affected patients.
How similar studies have performed: While the specific approach of monitoring platelet activation in this context may be novel, similar studies have explored the role of platelets in vascular dysfunction and delayed cerebral ischemia.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and Female Adults ≤18 years of age. * Hospitalised in the neurological intensive care unit of the Pierre Wertheimer Hospital of the Hospices Civils de Lyon following an aneurysmal meningeal haemorrhage of any modified Fischer score, previously diagnosed by cerebral CT scan. * Patients admitted to the neurological intensive care unit or the NICU of the Pierre Wertheimer Hospital of the Hospices Civils de Lyon for an intra-parenchymal haematoma. * Patient who has been informed and has formulated his/her non-opposition, or close relative of the patient who has been informed and has formulated his/her non-opposition. * Affiliated to a social security scheme. Exclusion Criteria: * Non-aneurysmal SAH * Ischaemic stroke * Patients with previously known platelet function disorders * Pregnant or breast-feeding women * Patients under legal protection (guardianship, curatorship, safeguard of justice) * Patients under compulsory psychiatric care * Patients taking part in a study which may interfere with the present study
Where this trial is running
Bron, Auvergne-Rhône-Alpes and 1 other locations
- Anaesthesiology and Intensive Care medicine department, Pierre Wertheimer hospital — Bron, Auvergne-Rhône-Alpes, France (Recruiting)
- Neurovascular intensive care unit department, Pierre Wertheimer hospital — Bron, Auvergnes-Rhones-Alpes, France (Recruiting)
Study contacts
- Principal investigator: Nicolas Chardon, MD;Msc — Intensive care department; Pierre Wertheimer Hospital
- Study coordinator: Nicolas Chardon, MD;Msc
- Email: nicolas.chardon@chu-lyon.fr
- Phone: 683396245
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.